US Stem Cell Inc (OTCMKTS:USRM) has been repeatedly and staunchly defending its 200-day simple moving average over the past month. This week saw another such test and hold, with the stock bouncing sharply in Wednesday’s action. The company recently generated some buzz with the announcement of the partnership between John Salley and Stem Cell Centers of Excellence.
According to the release, “On June 24, 2017, John Salley had his first stem cell procedure to harvest his own stem cells and create relief in his shoulders and knees. On the Ball, in keeping with our mantra to create ideas and opportunities to grow business, felt that John Salley would be a natural addition to enhance the national roll out of Stem Cell Centers of Excellence treatment clinics.”
US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function.
You can find out when $USRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
The company’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
According to company materials, “USRM is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.”
Those involved all seem to sense a great deal of synergy in the partnership:
“As a spokesperson for the vegan lifestyle and long-time friend of On the Ball, John has a keen understanding of how the body functions and how stem cell treatment is a natural alternative for the athlete community. John is a perfect conduit,” says Steve Nudelberg.
“I am excited to be part of the future with the team at Stem Cell Centers of Excellence. Two things jump to mind after my recent treatment: one, I can’t wait for my body to start healing itself and, two, I feel secure in knowing that my stem cells, which are not getting any younger, are now stored and will be ready should I need them for future use at any time,” says John Salley.
“Superstar athlete and wellness expert John Salley is the ideal individual to represent Stem Cell Centers of Excellence as we continue educating the public about the benefits of stem cells and the body’s ability to heal itself,” said Mike Tomas, President and CEO of USRM. “John has seen first-hand how injuries to athletes, and sports enthusiasts alike, can be devastating with long recovery times. Cutting-edge stem cell treatments for individuals with orthopedic as well as neurological conditions are an excellent option for these patients to improve their quality of life.”
The chart shows -9% stripped out of share pricing for the listing in the past week in a move that has reflected the general direction of affairs for this stock over recent months.
That said, one would be wise to recall that this stock has a long history rich with sharp and often astonishing rallies. Shorts do well to avoid overly leveraged exposure here. Moreover, the listing has benefitted from a jump in recent trading volume to the tune of 17% over the long run average.
Now commanding a market cap of $18.43M, US Stem Cell Inc (OTCMKTS:USRM) has a stash ($619K) of cash on the books, which stands against about $3.3M in total current liabilities. One should also note that debt has been growing over recent quarters. USRM is pulling in trailing 12-month revenues of $3.5M. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 62.5%. You can bet we will update this one again as new information comes into view. For continuing coverage on shares of $USRM stock, as well as our other breakout stock picks, sign up for our free newsletter today and get our next hot stock pick!
Disclosure: we hold no position in $USRM, either long or short, and we have not been compensated for this article.